PBM Act
Summary
The PBM Act (HR8779) would prohibit common ownership of pharmacy benefit managers and pharmacies, directly threatening the integrated business models of UnitedHealth, CVS Health, and Cigna. Although in early legislative stages, bipartisan sponsorship signals potential momentum.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.If passed, the bill forces divestitures of PBM or pharmacy assets from major integrated healthcare firms.
- 2.UnitedHealth, CVS Health, and Cigna face the highest structural and revenue risk.
- 3.Market pricing of this risk remains low due to early legislative stage; monitor committee activity.
Market Implications
The PBM Act introduces regulatory risk for the largest healthcare conglomerates. Currently, the market has not priced in this risk given the bill's early stage. If the bill gains traction—e.g., committee markup or bipartisan support grows—expect pressure on UNH, CVS, and CI as investors reassess the value of vertical integration. Conversely, independent pharmacies and PBM-focused companies without pharmacy ties could see relative benefit, but no such public companies are clearly isolated.
Full Analysis
The Patients Before Monopolies Act (PBM Act) was introduced on May 13, 2026, and referred to the House Committee on the Judiciary. It targets vertical integration in healthcare by barring PBMs and pharmacies from being under common ownership. The bill cites FTC findings that integrated PBMs steer patients to affiliated pharmacies, reducing competition and raising costs. No appropriation is involved; the bill imposes a structural prohibition. If enacted, UnitedHealth (UNH) would likely need to divest either OptumRx (PBM) or its Optum pharmacy network. CVS Health (CVS) would face a similar choice between Caremark (PBM) and CVS Pharmacy. Cigna (CI), through Express Scripts, would also be forced to spin off its PBM or exit pharmacy operations. Independent pharmacies could benefit from reduced self-preferencing, but no pure-play pharmacy tickers meet the causal chain threshold. The bill is early stage—only referred to committee—but has bipartisan sponsorship (7 cosponsors including both Republicans and Democrats). The legislative path requires committee markup, House passage, Senate consideration, and presidential action. Given the 119th Congress runs through 2027, there is time for development, but no immediate market impact is expected.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Prohibition of common ownership between PBM and pharmacy operations
Who must act
CVS Health (owns Caremark PBM and CVS Pharmacy retail chain)
What happens
Must divest either Caremark or CVS Pharmacy, disrupting integrated health services strategy and reducing profit from pharmacy benefit management
Stock impact
Caremark PBM and retail pharmacy together represent ~70% of CVS's revenue; forced separation would eliminate cross-segment efficiencies and potentially lower margins
What the bill does
Prohibition of common ownership between PBM and pharmacy operations
Who must act
Cigna (owns Express Scripts PBM and has pharmacy partnerships via Evernorth)
What happens
Must divest Express Scripts or exit pharmacy-related businesses, eliminating a key profit center and reducing bargaining power with drug manufacturers
Stock impact
Express Scripts accounts for ~60% of Cigna's total revenue; divestiture would remove the primary growth driver and lower EBITDA margins significantly
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.